nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—SLC6A4—Alzheimer's disease	0.158	0.405	CbGaD
Nefazodone—HTR2A—Alzheimer's disease	0.122	0.311	CbGaD
Nefazodone—HTR2A—Donepezil—Alzheimer's disease	0.116	0.388	CbGbCtD
Nefazodone—CYP2D6—Alzheimer's disease	0.111	0.284	CbGaD
Nefazodone—CYP2D6—Rivastigmine—Alzheimer's disease	0.0484	0.162	CbGbCtD
Nefazodone—CYP2D6—Donepezil—Alzheimer's disease	0.0387	0.129	CbGbCtD
Nefazodone—CYP3A4—Rivastigmine—Alzheimer's disease	0.0307	0.103	CbGbCtD
Nefazodone—CYP2D6—Galantamine—Alzheimer's disease	0.0249	0.0832	CbGbCtD
Nefazodone—CYP3A4—Donepezil—Alzheimer's disease	0.0246	0.0821	CbGbCtD
Nefazodone—CYP3A4—Galantamine—Alzheimer's disease	0.0158	0.0529	CbGbCtD
Nefazodone—HTR2C—choroid plexus—Alzheimer's disease	0.00987	0.166	CbGeAlD
Nefazodone—SLC6A2—locus ceruleus—Alzheimer's disease	0.00509	0.0854	CbGeAlD
Nefazodone—HTR2A—choroid plexus—Alzheimer's disease	0.00495	0.0831	CbGeAlD
Nefazodone—HTR2A—locus ceruleus—Alzheimer's disease	0.00306	0.0514	CbGeAlD
Nefazodone—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.00299	0.0502	CbGeAlD
Nefazodone—HTR2C—telencephalic ventricle—Alzheimer's disease	0.00289	0.0485	CbGeAlD
Nefazodone—HTR2A—cerebellar cortex—Alzheimer's disease	0.00249	0.0419	CbGeAlD
Nefazodone—HTR1A—telencephalic ventricle—Alzheimer's disease	0.00243	0.0409	CbGeAlD
Nefazodone—HTR2A—telencephalic ventricle—Alzheimer's disease	0.00145	0.0244	CbGeAlD
Nefazodone—SLC6A3—forebrain—Alzheimer's disease	0.000781	0.0131	CbGeAlD
Nefazodone—HTR2C—forebrain—Alzheimer's disease	0.000755	0.0127	CbGeAlD
Nefazodone—SLC6A3—telencephalon—Alzheimer's disease	0.000718	0.0121	CbGeAlD
Nefazodone—HTR2A—blood vessel—Alzheimer's disease	0.000718	0.0121	CbGeAlD
Nefazodone—SLC6A4—forebrain—Alzheimer's disease	0.000716	0.012	CbGeAlD
Nefazodone—HTR2C—telencephalon—Alzheimer's disease	0.000695	0.0117	CbGeAlD
Nefazodone—SLC6A4—telencephalon—Alzheimer's disease	0.000658	0.0111	CbGeAlD
Nefazodone—HTR1A—forebrain—Alzheimer's disease	0.000636	0.0107	CbGeAlD
Nefazodone—SLC6A2—forebrain—Alzheimer's disease	0.00063	0.0106	CbGeAlD
Nefazodone—ADRA1A—forebrain—Alzheimer's disease	0.000586	0.00984	CbGeAlD
Nefazodone—HTR1A—telencephalon—Alzheimer's disease	0.000585	0.00981	CbGeAlD
Nefazodone—SLC6A2—telencephalon—Alzheimer's disease	0.00058	0.00973	CbGeAlD
Nefazodone—ADRA1B—nervous system—Alzheimer's disease	0.000566	0.0095	CbGeAlD
Nefazodone—ADRA1B—central nervous system—Alzheimer's disease	0.000545	0.00915	CbGeAlD
Nefazodone—ADRA1A—telencephalon—Alzheimer's disease	0.000539	0.00904	CbGeAlD
Nefazodone—ABCB1—blood vessel—Alzheimer's disease	0.000471	0.0079	CbGeAlD
Nefazodone—ADRA2A—forebrain—Alzheimer's disease	0.000446	0.00748	CbGeAlD
Nefazodone—ADRA1B—brain—Alzheimer's disease	0.000433	0.00726	CbGeAlD
Nefazodone—HTR2A—embryo—Alzheimer's disease	0.000428	0.00719	CbGeAlD
Nefazodone—SLC6A3—nervous system—Alzheimer's disease	0.000424	0.00712	CbGeAlD
Nefazodone—HTR2C—nervous system—Alzheimer's disease	0.00041	0.00688	CbGeAlD
Nefazodone—ADRA2A—telencephalon—Alzheimer's disease	0.00041	0.00688	CbGeAlD
Nefazodone—SLC6A3—central nervous system—Alzheimer's disease	0.000408	0.00685	CbGeAlD
Nefazodone—SLC6A3—cerebellum—Alzheimer's disease	0.000399	0.0067	CbGeAlD
Nefazodone—HTR2C—central nervous system—Alzheimer's disease	0.000395	0.00663	CbGeAlD
Nefazodone—SLC6A4—nervous system—Alzheimer's disease	0.000389	0.00652	CbGeAlD
Nefazodone—HTR2A—forebrain—Alzheimer's disease	0.000379	0.00636	CbGeAlD
Nefazodone—SLC6A4—central nervous system—Alzheimer's disease	0.000374	0.00628	CbGeAlD
Nefazodone—Zuclopenthixol—HTR6—Alzheimer's disease	0.000366	0.0875	CrCbGaD
Nefazodone—HTR2A—telencephalon—Alzheimer's disease	0.000348	0.00585	CbGeAlD
Nefazodone—CYP2D6—forebrain—Alzheimer's disease	0.000345	0.00579	CbGeAlD
Nefazodone—HTR1A—nervous system—Alzheimer's disease	0.000345	0.00579	CbGeAlD
Nefazodone—SLC6A2—nervous system—Alzheimer's disease	0.000342	0.00574	CbGeAlD
Nefazodone—Aripiprazole—HTR6—Alzheimer's disease	0.000338	0.0809	CrCbGaD
Nefazodone—HTR1A—central nervous system—Alzheimer's disease	0.000332	0.00558	CbGeAlD
Nefazodone—SLC6A2—central nervous system—Alzheimer's disease	0.000329	0.00553	CbGeAlD
Nefazodone—HTR1A—cerebellum—Alzheimer's disease	0.000325	0.00545	CbGeAlD
Nefazodone—SLC6A3—brain—Alzheimer's disease	0.000324	0.00544	CbGeAlD
Nefazodone—ADRA1A—nervous system—Alzheimer's disease	0.000318	0.00534	CbGeAlD
Nefazodone—CYP2D6—telencephalon—Alzheimer's disease	0.000317	0.00533	CbGeAlD
Nefazodone—HTR2C—brain—Alzheimer's disease	0.000313	0.00526	CbGeAlD
Nefazodone—ADRA1A—central nervous system—Alzheimer's disease	0.000306	0.00514	CbGeAlD
Nefazodone—Fluphenazine—CALM1—Alzheimer's disease	0.000302	0.0723	CrCbGaD
Nefazodone—ADRA1A—cerebellum—Alzheimer's disease	0.000299	0.00502	CbGeAlD
Nefazodone—SLC6A4—brain—Alzheimer's disease	0.000297	0.00499	CbGeAlD
Nefazodone—ABCB1—embryo—Alzheimer's disease	0.000281	0.00471	CbGeAlD
Nefazodone—Fluphenazine—HTR6—Alzheimer's disease	0.000272	0.0652	CrCbGaD
Nefazodone—HTR1A—brain—Alzheimer's disease	0.000264	0.00443	CbGeAlD
Nefazodone—SLC6A2—brain—Alzheimer's disease	0.000262	0.00439	CbGeAlD
Nefazodone—ABCB1—forebrain—Alzheimer's disease	0.000248	0.00417	CbGeAlD
Nefazodone—ADRA1A—brain—Alzheimer's disease	0.000243	0.00408	CbGeAlD
Nefazodone—ADRA2A—nervous system—Alzheimer's disease	0.000242	0.00406	CbGeAlD
Nefazodone—Trifluoperazine—CALM1—Alzheimer's disease	0.000242	0.0578	CrCbGaD
Nefazodone—Perphenazine—CALM1—Alzheimer's disease	0.000239	0.0571	CrCbGaD
Nefazodone—ADRA2A—central nervous system—Alzheimer's disease	0.000233	0.00391	CbGeAlD
Nefazodone—ABCB1—telencephalon—Alzheimer's disease	0.000228	0.00383	CbGeAlD
Nefazodone—ADRA2A—cerebellum—Alzheimer's disease	0.000228	0.00382	CbGeAlD
Nefazodone—Trifluoperazine—HTR6—Alzheimer's disease	0.000218	0.0521	CrCbGaD
Nefazodone—Perphenazine—HTR6—Alzheimer's disease	0.000215	0.0515	CrCbGaD
Nefazodone—Loss of consciousness—Galantamine—Alzheimer's disease	0.000215	0.00114	CcSEcCtD
Nefazodone—Oedema peripheral—Donepezil—Alzheimer's disease	0.000214	0.00113	CcSEcCtD
Nefazodone—Urinary tract infection—Memantine—Alzheimer's disease	0.000214	0.00113	CcSEcCtD
Nefazodone—Conjunctivitis—Memantine—Alzheimer's disease	0.000214	0.00113	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.000213	0.00113	CcSEcCtD
Nefazodone—Cough—Galantamine—Alzheimer's disease	0.000213	0.00113	CcSEcCtD
Nefazodone—Convulsion—Galantamine—Alzheimer's disease	0.000212	0.00112	CcSEcCtD
Nefazodone—Quetiapine—HTR6—Alzheimer's disease	0.000211	0.0505	CrCbGaD
Nefazodone—Hypertension—Galantamine—Alzheimer's disease	0.000211	0.00112	CcSEcCtD
Nefazodone—Haematuria—Memantine—Alzheimer's disease	0.00021	0.00111	CcSEcCtD
Nefazodone—Visual impairment—Donepezil—Alzheimer's disease	0.00021	0.00111	CcSEcCtD
Nefazodone—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.000209	0.00111	CcSEcCtD
Nefazodone—Conjunctivitis—Rivastigmine—Alzheimer's disease	0.000209	0.00111	CcSEcCtD
Nefazodone—Arthralgia—Galantamine—Alzheimer's disease	0.000208	0.0011	CcSEcCtD
Nefazodone—Myalgia—Galantamine—Alzheimer's disease	0.000208	0.0011	CcSEcCtD
Nefazodone—Chest pain—Galantamine—Alzheimer's disease	0.000208	0.0011	CcSEcCtD
Nefazodone—Epistaxis—Memantine—Alzheimer's disease	0.000208	0.0011	CcSEcCtD
Nefazodone—Anxiety—Galantamine—Alzheimer's disease	0.000207	0.0011	CcSEcCtD
Nefazodone—Sinusitis—Memantine—Alzheimer's disease	0.000206	0.00109	CcSEcCtD
Nefazodone—Sweating—Rivastigmine—Alzheimer's disease	0.000206	0.00109	CcSEcCtD
Nefazodone—HTR2A—nervous system—Alzheimer's disease	0.000206	0.00345	CbGeAlD
Nefazodone—Discomfort—Galantamine—Alzheimer's disease	0.000206	0.00109	CcSEcCtD
Nefazodone—Haematuria—Rivastigmine—Alzheimer's disease	0.000205	0.00109	CcSEcCtD
Nefazodone—Dry mouth—Galantamine—Alzheimer's disease	0.000203	0.00108	CcSEcCtD
Nefazodone—Epistaxis—Rivastigmine—Alzheimer's disease	0.000203	0.00107	CcSEcCtD
Nefazodone—Tinnitus—Donepezil—Alzheimer's disease	0.000203	0.00107	CcSEcCtD
Nefazodone—Sinusitis—Rivastigmine—Alzheimer's disease	0.000202	0.00107	CcSEcCtD
Nefazodone—Confusional state—Galantamine—Alzheimer's disease	0.000201	0.00106	CcSEcCtD
Nefazodone—Bradycardia—Memantine—Alzheimer's disease	0.000201	0.00106	CcSEcCtD
Nefazodone—Haemoglobin—Memantine—Alzheimer's disease	0.000199	0.00105	CcSEcCtD
Nefazodone—Rhinitis—Memantine—Alzheimer's disease	0.000198	0.00105	CcSEcCtD
Nefazodone—HTR2A—central nervous system—Alzheimer's disease	0.000198	0.00332	CbGeAlD
Nefazodone—Hepatitis—Memantine—Alzheimer's disease	0.000198	0.00104	CcSEcCtD
Nefazodone—Haemorrhage—Memantine—Alzheimer's disease	0.000198	0.00104	CcSEcCtD
Nefazodone—Bradycardia—Rivastigmine—Alzheimer's disease	0.000197	0.00104	CcSEcCtD
Nefazodone—Hypoaesthesia—Memantine—Alzheimer's disease	0.000197	0.00104	CcSEcCtD
Nefazodone—Hallucination—Memantine—Alzheimer's disease	0.000197	0.00104	CcSEcCtD
Nefazodone—Shock—Galantamine—Alzheimer's disease	0.000196	0.00104	CcSEcCtD
Nefazodone—Pharyngitis—Memantine—Alzheimer's disease	0.000196	0.00104	CcSEcCtD
Nefazodone—Thrombocytopenia—Galantamine—Alzheimer's disease	0.000195	0.00103	CcSEcCtD
Nefazodone—Chills—Donepezil—Alzheimer's disease	0.000195	0.00103	CcSEcCtD
Nefazodone—Tachycardia—Galantamine—Alzheimer's disease	0.000195	0.00103	CcSEcCtD
Nefazodone—Oedema peripheral—Memantine—Alzheimer's disease	0.000195	0.00103	CcSEcCtD
Nefazodone—Haemoglobin—Rivastigmine—Alzheimer's disease	0.000194	0.00103	CcSEcCtD
Nefazodone—Rhinitis—Rivastigmine—Alzheimer's disease	0.000194	0.00102	CcSEcCtD
Nefazodone—HTR2A—cerebellum—Alzheimer's disease	0.000194	0.00325	CbGeAlD
Nefazodone—Hepatitis—Rivastigmine—Alzheimer's disease	0.000193	0.00102	CcSEcCtD
Nefazodone—Haemorrhage—Rivastigmine—Alzheimer's disease	0.000193	0.00102	CcSEcCtD
Nefazodone—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000193	0.00102	CcSEcCtD
Nefazodone—Hallucination—Rivastigmine—Alzheimer's disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Alopecia—Donepezil—Alzheimer's disease	0.000192	0.00102	CcSEcCtD
Nefazodone—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000192	0.00101	CcSEcCtD
Nefazodone—CYP3A4—nervous system—Alzheimer's disease	0.00019	0.0032	CbGeAlD
Nefazodone—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Visual impairment—Memantine—Alzheimer's disease	0.00019	0.00101	CcSEcCtD
Nefazodone—Anorexia—Galantamine—Alzheimer's disease	0.00019	0.00101	CcSEcCtD
Nefazodone—CYP2D6—nervous system—Alzheimer's disease	0.000187	0.00314	CbGeAlD
Nefazodone—Erythema multiforme—Memantine—Alzheimer's disease	0.000187	0.000988	CcSEcCtD
Nefazodone—Flatulence—Donepezil—Alzheimer's disease	0.000187	0.000987	CcSEcCtD
Nefazodone—Hypotension—Galantamine—Alzheimer's disease	0.000186	0.000986	CcSEcCtD
Nefazodone—Visual impairment—Rivastigmine—Alzheimer's disease	0.000186	0.000985	CcSEcCtD
Nefazodone—Dysgeusia—Donepezil—Alzheimer's disease	0.000185	0.000981	CcSEcCtD
Nefazodone—ADRA2A—brain—Alzheimer's disease	0.000185	0.0031	CbGeAlD
Nefazodone—Tinnitus—Memantine—Alzheimer's disease	0.000184	0.000974	CcSEcCtD
Nefazodone—Flushing—Memantine—Alzheimer's disease	0.000183	0.00097	CcSEcCtD
Nefazodone—CYP3A4—central nervous system—Alzheimer's disease	0.000183	0.00308	CbGeAlD
Nefazodone—Back pain—Donepezil—Alzheimer's disease	0.000183	0.000969	CcSEcCtD
Nefazodone—Hydroxyzine—CYP2D6—Alzheimer's disease	0.000183	0.0437	CrCbGaD
Nefazodone—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000183	0.000966	CcSEcCtD
Nefazodone—Muscle spasms—Donepezil—Alzheimer's disease	0.000182	0.000963	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000182	0.000961	CcSEcCtD
Nefazodone—Insomnia—Galantamine—Alzheimer's disease	0.00018	0.000954	CcSEcCtD
Nefazodone—CYP2D6—central nervous system—Alzheimer's disease	0.00018	0.00303	CbGeAlD
Nefazodone—Tinnitus—Rivastigmine—Alzheimer's disease	0.00018	0.000953	CcSEcCtD
Nefazodone—Flushing—Rivastigmine—Alzheimer's disease	0.000179	0.000949	CcSEcCtD
Nefazodone—Paraesthesia—Galantamine—Alzheimer's disease	0.000179	0.000947	CcSEcCtD
Nefazodone—Vision blurred—Donepezil—Alzheimer's disease	0.000179	0.000944	CcSEcCtD
Nefazodone—Tremor—Donepezil—Alzheimer's disease	0.000177	0.000938	CcSEcCtD
Nefazodone—Somnolence—Galantamine—Alzheimer's disease	0.000177	0.000938	CcSEcCtD
Nefazodone—Chills—Memantine—Alzheimer's disease	0.000177	0.000937	CcSEcCtD
Nefazodone—CYP2D6—cerebellum—Alzheimer's disease	0.000176	0.00296	CbGeAlD
Nefazodone—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000176	0.000929	CcSEcCtD
Nefazodone—Dyspepsia—Galantamine—Alzheimer's disease	0.000176	0.000929	CcSEcCtD
Nefazodone—Anaemia—Donepezil—Alzheimer's disease	0.000175	0.000926	CcSEcCtD
Nefazodone—Alopecia—Memantine—Alzheimer's disease	0.000175	0.000923	CcSEcCtD
Nefazodone—Agitation—Donepezil—Alzheimer's disease	0.000174	0.000921	CcSEcCtD
Nefazodone—Chills—Rivastigmine—Alzheimer's disease	0.000173	0.000917	CcSEcCtD
Nefazodone—Decreased appetite—Galantamine—Alzheimer's disease	0.000173	0.000917	CcSEcCtD
Nefazodone—Malaise—Donepezil—Alzheimer's disease	0.000171	0.000903	CcSEcCtD
Nefazodone—Alopecia—Rivastigmine—Alzheimer's disease	0.000171	0.000903	CcSEcCtD
Nefazodone—Constipation—Galantamine—Alzheimer's disease	0.000171	0.000902	CcSEcCtD
Nefazodone—Vertigo—Donepezil—Alzheimer's disease	0.00017	0.0009	CcSEcCtD
Nefazodone—Syncope—Donepezil—Alzheimer's disease	0.00017	0.000898	CcSEcCtD
Nefazodone—Flatulence—Memantine—Alzheimer's disease	0.000169	0.000896	CcSEcCtD
Nefazodone—Dysgeusia—Memantine—Alzheimer's disease	0.000168	0.000891	CcSEcCtD
Nefazodone—Loss of consciousness—Donepezil—Alzheimer's disease	0.000166	0.00088	CcSEcCtD
Nefazodone—Back pain—Memantine—Alzheimer's disease	0.000166	0.00088	CcSEcCtD
Nefazodone—Flatulence—Rivastigmine—Alzheimer's disease	0.000166	0.000877	CcSEcCtD
Nefazodone—Cough—Donepezil—Alzheimer's disease	0.000165	0.000874	CcSEcCtD
Nefazodone—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000165	0.000871	CcSEcCtD
Nefazodone—Feeling abnormal—Galantamine—Alzheimer's disease	0.000164	0.000869	CcSEcCtD
Nefazodone—Convulsion—Donepezil—Alzheimer's disease	0.000164	0.000868	CcSEcCtD
Nefazodone—Hypertension—Donepezil—Alzheimer's disease	0.000164	0.000865	CcSEcCtD
Nefazodone—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000163	0.000863	CcSEcCtD
Nefazodone—Back pain—Rivastigmine—Alzheimer's disease	0.000163	0.000861	CcSEcCtD
Nefazodone—Vision blurred—Memantine—Alzheimer's disease	0.000162	0.000857	CcSEcCtD
Nefazodone—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000162	0.000855	CcSEcCtD
Nefazodone—Chest pain—Donepezil—Alzheimer's disease	0.000161	0.000853	CcSEcCtD
Nefazodone—Myalgia—Donepezil—Alzheimer's disease	0.000161	0.000853	CcSEcCtD
Nefazodone—Arthralgia—Donepezil—Alzheimer's disease	0.000161	0.000853	CcSEcCtD
Nefazodone—Tremor—Memantine—Alzheimer's disease	0.000161	0.000852	CcSEcCtD
Nefazodone—Anxiety—Donepezil—Alzheimer's disease	0.000161	0.00085	CcSEcCtD
Nefazodone—Ill-defined disorder—Memantine—Alzheimer's disease	0.00016	0.000844	CcSEcCtD
Nefazodone—Discomfort—Donepezil—Alzheimer's disease	0.000159	0.000843	CcSEcCtD
Nefazodone—Anaemia—Memantine—Alzheimer's disease	0.000159	0.000841	CcSEcCtD
Nefazodone—Vision blurred—Rivastigmine—Alzheimer's disease	0.000159	0.000839	CcSEcCtD
Nefazodone—Agitation—Memantine—Alzheimer's disease	0.000158	0.000836	CcSEcCtD
Nefazodone—Dry mouth—Donepezil—Alzheimer's disease	0.000158	0.000834	CcSEcCtD
Nefazodone—Body temperature increased—Galantamine—Alzheimer's disease	0.000158	0.000834	CcSEcCtD
Nefazodone—Abdominal pain—Galantamine—Alzheimer's disease	0.000158	0.000834	CcSEcCtD
Nefazodone—Tremor—Rivastigmine—Alzheimer's disease	0.000158	0.000834	CcSEcCtD
Nefazodone—HTR2A—brain—Alzheimer's disease	0.000157	0.00264	CbGeAlD
Nefazodone—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000156	0.000826	CcSEcCtD
Nefazodone—Confusional state—Donepezil—Alzheimer's disease	0.000156	0.000824	CcSEcCtD
Nefazodone—Anaemia—Rivastigmine—Alzheimer's disease	0.000155	0.000822	CcSEcCtD
Nefazodone—Malaise—Memantine—Alzheimer's disease	0.000155	0.00082	CcSEcCtD
Nefazodone—Agitation—Rivastigmine—Alzheimer's disease	0.000155	0.000818	CcSEcCtD
Nefazodone—Oedema—Donepezil—Alzheimer's disease	0.000155	0.000818	CcSEcCtD
Nefazodone—Vertigo—Memantine—Alzheimer's disease	0.000155	0.000817	CcSEcCtD
Nefazodone—Syncope—Memantine—Alzheimer's disease	0.000154	0.000816	CcSEcCtD
Nefazodone—Leukopenia—Memantine—Alzheimer's disease	0.000154	0.000814	CcSEcCtD
Nefazodone—Infection—Donepezil—Alzheimer's disease	0.000154	0.000812	CcSEcCtD
Nefazodone—Shock—Donepezil—Alzheimer's disease	0.000152	0.000804	CcSEcCtD
Nefazodone—Palpitations—Memantine—Alzheimer's disease	0.000152	0.000804	CcSEcCtD
Nefazodone—Malaise—Rivastigmine—Alzheimer's disease	0.000152	0.000802	CcSEcCtD
Nefazodone—Thrombocytopenia—Donepezil—Alzheimer's disease	0.000151	0.0008	CcSEcCtD
Nefazodone—Vertigo—Rivastigmine—Alzheimer's disease	0.000151	0.000799	CcSEcCtD
Nefazodone—Loss of consciousness—Memantine—Alzheimer's disease	0.000151	0.000799	CcSEcCtD
Nefazodone—Syncope—Rivastigmine—Alzheimer's disease	0.000151	0.000798	CcSEcCtD
Nefazodone—Cough—Memantine—Alzheimer's disease	0.00015	0.000794	CcSEcCtD
Nefazodone—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000149	0.00079	CcSEcCtD
Nefazodone—Convulsion—Memantine—Alzheimer's disease	0.000149	0.000788	CcSEcCtD
Nefazodone—Palpitations—Rivastigmine—Alzheimer's disease	0.000149	0.000786	CcSEcCtD
Nefazodone—Hypertension—Memantine—Alzheimer's disease	0.000148	0.000785	CcSEcCtD
Nefazodone—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000148	0.000782	CcSEcCtD
Nefazodone—Anorexia—Donepezil—Alzheimer's disease	0.000147	0.000779	CcSEcCtD
Nefazodone—Hypersensitivity—Galantamine—Alzheimer's disease	0.000147	0.000777	CcSEcCtD
Nefazodone—Cough—Rivastigmine—Alzheimer's disease	0.000147	0.000776	CcSEcCtD
Nefazodone—Chest pain—Memantine—Alzheimer's disease	0.000146	0.000774	CcSEcCtD
Nefazodone—Arthralgia—Memantine—Alzheimer's disease	0.000146	0.000774	CcSEcCtD
Nefazodone—Myalgia—Memantine—Alzheimer's disease	0.000146	0.000774	CcSEcCtD
Nefazodone—Anxiety—Memantine—Alzheimer's disease	0.000146	0.000772	CcSEcCtD
Nefazodone—Convulsion—Rivastigmine—Alzheimer's disease	0.000146	0.000771	CcSEcCtD
Nefazodone—Hypertension—Rivastigmine—Alzheimer's disease	0.000145	0.000768	CcSEcCtD
Nefazodone—Discomfort—Memantine—Alzheimer's disease	0.000145	0.000765	CcSEcCtD
Nefazodone—Hypotension—Donepezil—Alzheimer's disease	0.000144	0.000764	CcSEcCtD
Nefazodone—Chest pain—Rivastigmine—Alzheimer's disease	0.000143	0.000757	CcSEcCtD
Nefazodone—Myalgia—Rivastigmine—Alzheimer's disease	0.000143	0.000757	CcSEcCtD
Nefazodone—Arthralgia—Rivastigmine—Alzheimer's disease	0.000143	0.000757	CcSEcCtD
Nefazodone—CYP2D6—brain—Alzheimer's disease	0.000143	0.0024	CbGeAlD
Nefazodone—Dry mouth—Memantine—Alzheimer's disease	0.000143	0.000757	CcSEcCtD
Nefazodone—Asthenia—Galantamine—Alzheimer's disease	0.000143	0.000757	CcSEcCtD
Nefazodone—Anxiety—Rivastigmine—Alzheimer's disease	0.000143	0.000755	CcSEcCtD
Nefazodone—Confusional state—Memantine—Alzheimer's disease	0.000142	0.000748	CcSEcCtD
Nefazodone—Discomfort—Rivastigmine—Alzheimer's disease	0.000142	0.000748	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.000141	0.000745	CcSEcCtD
Nefazodone—Oedema—Memantine—Alzheimer's disease	0.00014	0.000742	CcSEcCtD
Nefazodone—Dry mouth—Rivastigmine—Alzheimer's disease	0.00014	0.000741	CcSEcCtD
Nefazodone—Insomnia—Donepezil—Alzheimer's disease	0.00014	0.000739	CcSEcCtD
Nefazodone—Infection—Memantine—Alzheimer's disease	0.000139	0.000737	CcSEcCtD
Nefazodone—Paraesthesia—Donepezil—Alzheimer's disease	0.000139	0.000734	CcSEcCtD
Nefazodone—Confusional state—Rivastigmine—Alzheimer's disease	0.000138	0.000732	CcSEcCtD
Nefazodone—Shock—Memantine—Alzheimer's disease	0.000138	0.00073	CcSEcCtD
Nefazodone—Dyspnoea—Donepezil—Alzheimer's disease	0.000138	0.000729	CcSEcCtD
Nefazodone—Somnolence—Donepezil—Alzheimer's disease	0.000137	0.000727	CcSEcCtD
Nefazodone—Thrombocytopenia—Memantine—Alzheimer's disease	0.000137	0.000727	CcSEcCtD
Nefazodone—Oedema—Rivastigmine—Alzheimer's disease	0.000137	0.000726	CcSEcCtD
Nefazodone—Tachycardia—Memantine—Alzheimer's disease	0.000137	0.000724	CcSEcCtD
Nefazodone—Diarrhoea—Galantamine—Alzheimer's disease	0.000136	0.000722	CcSEcCtD
Nefazodone—Infection—Rivastigmine—Alzheimer's disease	0.000136	0.000721	CcSEcCtD
Nefazodone—Dyspepsia—Donepezil—Alzheimer's disease	0.000136	0.00072	CcSEcCtD
Nefazodone—Hyperhidrosis—Memantine—Alzheimer's disease	0.000136	0.000718	CcSEcCtD
Nefazodone—Shock—Rivastigmine—Alzheimer's disease	0.000135	0.000714	CcSEcCtD
Nefazodone—ABCB1—nervous system—Alzheimer's disease	0.000135	0.00226	CbGeAlD
Nefazodone—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000134	0.000711	CcSEcCtD
Nefazodone—Decreased appetite—Donepezil—Alzheimer's disease	0.000134	0.000711	CcSEcCtD
Nefazodone—Tachycardia—Rivastigmine—Alzheimer's disease	0.000134	0.000709	CcSEcCtD
Nefazodone—Anorexia—Memantine—Alzheimer's disease	0.000134	0.000708	CcSEcCtD
Nefazodone—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000133	0.000702	CcSEcCtD
Nefazodone—Constipation—Donepezil—Alzheimer's disease	0.000132	0.000699	CcSEcCtD
Nefazodone—Pain—Donepezil—Alzheimer's disease	0.000132	0.000699	CcSEcCtD
Nefazodone—Dizziness—Galantamine—Alzheimer's disease	0.000132	0.000698	CcSEcCtD
Nefazodone—Hypotension—Memantine—Alzheimer's disease	0.000131	0.000694	CcSEcCtD
Nefazodone—Anorexia—Rivastigmine—Alzheimer's disease	0.000131	0.000692	CcSEcCtD
Nefazodone—ABCB1—central nervous system—Alzheimer's disease	0.00013	0.00218	CbGeAlD
Nefazodone—Aripiprazole—SLC6A4—Alzheimer's disease	0.000129	0.031	CrCbGaD
Nefazodone—Trazodone—SLC6A4—Alzheimer's disease	0.000129	0.0308	CrCbGaD
Nefazodone—Hypotension—Rivastigmine—Alzheimer's disease	0.000128	0.000679	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000128	0.000676	CcSEcCtD
Nefazodone—Feeling abnormal—Donepezil—Alzheimer's disease	0.000127	0.000674	CcSEcCtD
Nefazodone—Insomnia—Memantine—Alzheimer's disease	0.000127	0.000671	CcSEcCtD
Nefazodone—ABCB1—cerebellum—Alzheimer's disease	0.000127	0.00213	CbGeAlD
Nefazodone—Vomiting—Galantamine—Alzheimer's disease	0.000127	0.000671	CcSEcCtD
Nefazodone—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000126	0.000669	CcSEcCtD
Nefazodone—Paraesthesia—Memantine—Alzheimer's disease	0.000126	0.000667	CcSEcCtD
Nefazodone—Rash—Galantamine—Alzheimer's disease	0.000126	0.000665	CcSEcCtD
Nefazodone—Dermatitis—Galantamine—Alzheimer's disease	0.000126	0.000665	CcSEcCtD
Nefazodone—Dyspnoea—Memantine—Alzheimer's disease	0.000125	0.000662	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000125	0.000662	CcSEcCtD
Nefazodone—Headache—Galantamine—Alzheimer's disease	0.000125	0.000661	CcSEcCtD
Nefazodone—Somnolence—Memantine—Alzheimer's disease	0.000125	0.00066	CcSEcCtD
Nefazodone—Insomnia—Rivastigmine—Alzheimer's disease	0.000124	0.000657	CcSEcCtD
Nefazodone—Dyspepsia—Memantine—Alzheimer's disease	0.000124	0.000653	CcSEcCtD
Nefazodone—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000123	0.000652	CcSEcCtD
Nefazodone—Urticaria—Donepezil—Alzheimer's disease	0.000123	0.000649	CcSEcCtD
Nefazodone—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000122	0.000647	CcSEcCtD
Nefazodone—Body temperature increased—Donepezil—Alzheimer's disease	0.000122	0.000646	CcSEcCtD
Nefazodone—Abdominal pain—Donepezil—Alzheimer's disease	0.000122	0.000646	CcSEcCtD
Nefazodone—Somnolence—Rivastigmine—Alzheimer's disease	0.000122	0.000646	CcSEcCtD
Nefazodone—Decreased appetite—Memantine—Alzheimer's disease	0.000122	0.000645	CcSEcCtD
Nefazodone—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000121	0.000639	CcSEcCtD
Nefazodone—Constipation—Memantine—Alzheimer's disease	0.00012	0.000635	CcSEcCtD
Nefazodone—Pain—Memantine—Alzheimer's disease	0.00012	0.000635	CcSEcCtD
Nefazodone—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000119	0.000631	CcSEcCtD
Nefazodone—Nausea—Galantamine—Alzheimer's disease	0.000118	0.000627	CcSEcCtD
Nefazodone—Domperidone—CYP2D6—Alzheimer's disease	0.000118	0.0282	CrCbGaD
Nefazodone—Pain—Rivastigmine—Alzheimer's disease	0.000117	0.000621	CcSEcCtD
Nefazodone—Constipation—Rivastigmine—Alzheimer's disease	0.000117	0.000621	CcSEcCtD
Nefazodone—Feeling abnormal—Memantine—Alzheimer's disease	0.000116	0.000612	CcSEcCtD
Nefazodone—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000115	0.000607	CcSEcCtD
Nefazodone—Hypersensitivity—Donepezil—Alzheimer's disease	0.000114	0.000602	CcSEcCtD
Nefazodone—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000113	0.000598	CcSEcCtD
Nefazodone—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000112	0.000594	CcSEcCtD
Nefazodone—Urticaria—Memantine—Alzheimer's disease	0.000112	0.00059	CcSEcCtD
Nefazodone—Body temperature increased—Memantine—Alzheimer's disease	0.000111	0.000587	CcSEcCtD
Nefazodone—Abdominal pain—Memantine—Alzheimer's disease	0.000111	0.000587	CcSEcCtD
Nefazodone—Asthenia—Donepezil—Alzheimer's disease	0.000111	0.000587	CcSEcCtD
Nefazodone—Pruritus—Donepezil—Alzheimer's disease	0.000109	0.000578	CcSEcCtD
Nefazodone—Urticaria—Rivastigmine—Alzheimer's disease	0.000109	0.000577	CcSEcCtD
Nefazodone—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000109	0.000574	CcSEcCtD
Nefazodone—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000109	0.000574	CcSEcCtD
Nefazodone—Zuclopenthixol—HTR2A—Alzheimer's disease	0.000108	0.0257	CrCbGaD
Nefazodone—Diarrhoea—Donepezil—Alzheimer's disease	0.000106	0.000559	CcSEcCtD
Nefazodone—Hypersensitivity—Memantine—Alzheimer's disease	0.000103	0.000547	CcSEcCtD
Nefazodone—ABCB1—brain—Alzheimer's disease	0.000103	0.00173	CbGeAlD
Nefazodone—Dizziness—Donepezil—Alzheimer's disease	0.000102	0.000541	CcSEcCtD
Nefazodone—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000101	0.000535	CcSEcCtD
Nefazodone—Asthenia—Memantine—Alzheimer's disease	0.000101	0.000533	CcSEcCtD
Nefazodone—Aripiprazole—HTR2A—Alzheimer's disease	9.94e-05	0.0238	CrCbGaD
Nefazodone—Pruritus—Memantine—Alzheimer's disease	9.93e-05	0.000525	CcSEcCtD
Nefazodone—Trazodone—HTR2A—Alzheimer's disease	9.9e-05	0.0237	CrCbGaD
Nefazodone—Asthenia—Rivastigmine—Alzheimer's disease	9.85e-05	0.000521	CcSEcCtD
Nefazodone—Zuclopenthixol—CYP2D6—Alzheimer's disease	9.84e-05	0.0235	CrCbGaD
Nefazodone—Vomiting—Donepezil—Alzheimer's disease	9.83e-05	0.00052	CcSEcCtD
Nefazodone—Rash—Donepezil—Alzheimer's disease	9.75e-05	0.000515	CcSEcCtD
Nefazodone—Dermatitis—Donepezil—Alzheimer's disease	9.74e-05	0.000515	CcSEcCtD
Nefazodone—Pruritus—Rivastigmine—Alzheimer's disease	9.71e-05	0.000514	CcSEcCtD
Nefazodone—Headache—Donepezil—Alzheimer's disease	9.68e-05	0.000512	CcSEcCtD
Nefazodone—Diarrhoea—Memantine—Alzheimer's disease	9.6e-05	0.000508	CcSEcCtD
Nefazodone—Thioproperazine—HTR2A—Alzheimer's disease	9.43e-05	0.0225	CrCbGaD
Nefazodone—Diarrhoea—Rivastigmine—Alzheimer's disease	9.39e-05	0.000497	CcSEcCtD
Nefazodone—Dizziness—Memantine—Alzheimer's disease	9.28e-05	0.000491	CcSEcCtD
Nefazodone—Nausea—Donepezil—Alzheimer's disease	9.18e-05	0.000486	CcSEcCtD
Nefazodone—Aripiprazole—CYP2D6—Alzheimer's disease	9.09e-05	0.0218	CrCbGaD
Nefazodone—Dizziness—Rivastigmine—Alzheimer's disease	9.08e-05	0.00048	CcSEcCtD
Nefazodone—Trazodone—CYP2D6—Alzheimer's disease	9.05e-05	0.0216	CrCbGaD
Nefazodone—Vomiting—Memantine—Alzheimer's disease	8.92e-05	0.000472	CcSEcCtD
Nefazodone—Rash—Memantine—Alzheimer's disease	8.85e-05	0.000468	CcSEcCtD
Nefazodone—Dermatitis—Memantine—Alzheimer's disease	8.84e-05	0.000468	CcSEcCtD
Nefazodone—Headache—Memantine—Alzheimer's disease	8.79e-05	0.000465	CcSEcCtD
Nefazodone—Vomiting—Rivastigmine—Alzheimer's disease	8.73e-05	0.000462	CcSEcCtD
Nefazodone—Rash—Rivastigmine—Alzheimer's disease	8.66e-05	0.000458	CcSEcCtD
Nefazodone—Dermatitis—Rivastigmine—Alzheimer's disease	8.65e-05	0.000457	CcSEcCtD
Nefazodone—Headache—Rivastigmine—Alzheimer's disease	8.6e-05	0.000455	CcSEcCtD
Nefazodone—Nausea—Memantine—Alzheimer's disease	8.34e-05	0.000441	CcSEcCtD
Nefazodone—Nausea—Rivastigmine—Alzheimer's disease	8.16e-05	0.000431	CcSEcCtD
Nefazodone—Prochlorperazine—CYP2D6—Alzheimer's disease	8.11e-05	0.0194	CrCbGaD
Nefazodone—Fluphenazine—HTR2A—Alzheimer's disease	8.02e-05	0.0192	CrCbGaD
Nefazodone—Fluphenazine—CYP2D6—Alzheimer's disease	7.33e-05	0.0175	CrCbGaD
Nefazodone—Trifluoperazine—HTR2A—Alzheimer's disease	6.41e-05	0.0153	CrCbGaD
Nefazodone—Perphenazine—HTR2A—Alzheimer's disease	6.34e-05	0.0152	CrCbGaD
Nefazodone—Quetiapine—HTR2A—Alzheimer's disease	6.22e-05	0.0149	CrCbGaD
Nefazodone—Perphenazine—CYP2D6—Alzheimer's disease	5.8e-05	0.0139	CrCbGaD
Nefazodone—Quetiapine—CYP2D6—Alzheimer's disease	5.68e-05	0.0136	CrCbGaD
Nefazodone—CYP2D6—Metabolism—ENO1—Alzheimer's disease	5.33e-06	9.41e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	5.33e-06	9.41e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCR5—Alzheimer's disease	5.32e-06	9.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF2—Alzheimer's disease	5.3e-06	9.35e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—BCHE—Alzheimer's disease	5.26e-06	9.28e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NGF—Alzheimer's disease	5.24e-06	9.24e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HTR2A—Alzheimer's disease	5.24e-06	9.24e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1R—Alzheimer's disease	5.23e-06	9.24e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HTR2A—Alzheimer's disease	5.21e-06	9.19e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—S100B—Alzheimer's disease	5.17e-06	9.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1R—Alzheimer's disease	5.12e-06	9.04e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCR5—Alzheimer's disease	5.1e-06	8.99e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PPARG—Alzheimer's disease	5.05e-06	8.92e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LPL—Alzheimer's disease	5.02e-06	8.85e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—LPL—Alzheimer's disease	5e-06	8.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HTR2A—Alzheimer's disease	4.99e-06	8.8e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MEF2C—Alzheimer's disease	4.97e-06	8.78e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PLCB1—Alzheimer's disease	4.96e-06	8.76e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—BCHE—Alzheimer's disease	4.96e-06	8.75e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—INS—Alzheimer's disease	4.96e-06	8.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF2—Alzheimer's disease	4.92e-06	8.69e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—MTHFR—Alzheimer's disease	4.91e-06	8.67e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LPL—Alzheimer's disease	4.91e-06	8.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CALM1—Alzheimer's disease	4.89e-06	8.62e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PRKCG—Alzheimer's disease	4.88e-06	8.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MEF2C—Alzheimer's disease	4.87e-06	8.59e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—APOE—Alzheimer's disease	4.87e-06	8.59e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—LEP—Alzheimer's disease	4.87e-06	8.59e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CALM1—Alzheimer's disease	4.86e-06	8.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—LEP—Alzheimer's disease	4.84e-06	8.55e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—APOE—Alzheimer's disease	4.84e-06	8.55e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CAV1—Alzheimer's disease	4.82e-06	8.51e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ABCA1—Alzheimer's disease	4.81e-06	8.49e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CAV1—Alzheimer's disease	4.8e-06	8.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CHAT—Alzheimer's disease	4.8e-06	8.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TPI1—Alzheimer's disease	4.8e-06	8.47e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PRKCG—Alzheimer's disease	4.78e-06	8.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1R—Alzheimer's disease	4.76e-06	8.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NGF—Alzheimer's disease	4.75e-06	8.39e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	4.68e-06	8.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NGF—Alzheimer's disease	4.65e-06	8.21e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CALM1—Alzheimer's disease	4.65e-06	8.21e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ESR1—Alzheimer's disease	4.65e-06	8.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—APOE—Alzheimer's disease	4.64e-06	8.18e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—LEP—Alzheimer's disease	4.64e-06	8.18e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ESR1—Alzheimer's disease	4.62e-06	8.16e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCR5—Alzheimer's disease	4.62e-06	8.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—Alzheimer's disease	4.6e-06	8.12e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MAOB—Alzheimer's disease	4.6e-06	8.12e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CAV1—Alzheimer's disease	4.59e-06	8.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CALM1—Alzheimer's disease	4.59e-06	8.1e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—F2—Alzheimer's disease	4.59e-06	8.1e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—APOE—Alzheimer's disease	4.58e-06	8.08e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—F2—Alzheimer's disease	4.57e-06	8.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LPL—Alzheimer's disease	4.56e-06	8.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CAV1—Alzheimer's disease	4.53e-06	8e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	4.53e-06	8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCR5—Alzheimer's disease	4.53e-06	7.99e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MEF2C—Alzheimer's disease	4.52e-06	7.98e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—MTHFR—Alzheimer's disease	4.5e-06	7.95e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOTCH1—Alzheimer's disease	4.49e-06	7.93e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOTCH1—Alzheimer's disease	4.47e-06	7.89e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PRKCG—Alzheimer's disease	4.44e-06	7.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HTR2A—Alzheimer's disease	4.43e-06	7.82e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GAPDH—Alzheimer's disease	4.43e-06	7.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ESR1—Alzheimer's disease	4.43e-06	7.81e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—F2—Alzheimer's disease	4.37e-06	7.72e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NOS3—Alzheimer's disease	4.35e-06	7.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NGF—Alzheimer's disease	4.32e-06	7.63e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOTCH1—Alzheimer's disease	4.28e-06	7.55e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—A2M—Alzheimer's disease	4.28e-06	7.55e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CALM1—Alzheimer's disease	4.22e-06	7.45e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GSK3B—Alzheimer's disease	4.22e-06	7.44e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CALM1—Alzheimer's disease	4.21e-06	7.43e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—APOE—Alzheimer's disease	4.21e-06	7.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCR5—Alzheimer's disease	4.21e-06	7.42e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—LEP—Alzheimer's disease	4.21e-06	7.42e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GSK3B—Alzheimer's disease	4.19e-06	7.4e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—APOE—Alzheimer's disease	4.19e-06	7.4e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CREB1—Alzheimer's disease	4.18e-06	7.38e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CAV1—Alzheimer's disease	4.17e-06	7.35e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CREB1—Alzheimer's disease	4.16e-06	7.34e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—INS—Alzheimer's disease	4.16e-06	7.34e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CAV1—Alzheimer's disease	4.15e-06	7.33e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARGC1A—Alzheimer's disease	4.15e-06	7.32e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—INS—Alzheimer's disease	4.14e-06	7.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CALM1—Alzheimer's disease	4.13e-06	7.29e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—HMOX1—Alzheimer's disease	4.13e-06	7.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—APOE—Alzheimer's disease	4.12e-06	7.27e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—LEP—Alzheimer's disease	4.12e-06	7.27e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HTR2A—Alzheimer's disease	4.12e-06	7.26e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCL2—Alzheimer's disease	4.09e-06	7.22e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CAV1—Alzheimer's disease	4.08e-06	7.2e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCL2—Alzheimer's disease	4.07e-06	7.18e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1—Alzheimer's disease	4.02e-06	7.1e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ESR1—Alzheimer's disease	4.02e-06	7.09e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GSK3B—Alzheimer's disease	4.01e-06	7.09e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1—Alzheimer's disease	4e-06	7.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PPARG—Alzheimer's disease	3.99e-06	7.03e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CREB1—Alzheimer's disease	3.98e-06	7.03e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—Alzheimer's disease	3.97e-06	7.01e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—F2—Alzheimer's disease	3.97e-06	7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—INS—Alzheimer's disease	3.96e-06	6.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ESR1—Alzheimer's disease	3.93e-06	6.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—INS—Alzheimer's disease	3.91e-06	6.9e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	3.91e-06	6.9e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCL2—Alzheimer's disease	3.9e-06	6.88e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	3.89e-06	6.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—AKT1—Alzheimer's disease	3.89e-06	6.86e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—F2—Alzheimer's disease	3.88e-06	6.85e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.88e-06	6.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CALM1—Alzheimer's disease	3.84e-06	6.78e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1—Alzheimer's disease	3.83e-06	6.76e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—LEP—Alzheimer's disease	3.83e-06	6.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—APOE—Alzheimer's disease	3.83e-06	6.75e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.8e-06	6.71e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CAV1—Alzheimer's disease	3.79e-06	6.69e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—LPL—Alzheimer's disease	3.77e-06	6.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ACHE—Alzheimer's disease	3.72e-06	6.56e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INPP5D—Alzheimer's disease	3.68e-06	6.49e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ESR1—Alzheimer's disease	3.65e-06	6.45e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PPARG—Alzheimer's disease	3.65e-06	6.45e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—NOS3—Alzheimer's disease	3.65e-06	6.44e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.64e-06	6.43e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—NOS3—Alzheimer's disease	3.63e-06	6.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CREB1—Alzheimer's disease	3.61e-06	6.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—F2—Alzheimer's disease	3.61e-06	6.37e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—INS—Alzheimer's disease	3.59e-06	6.34e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—INS—Alzheimer's disease	3.58e-06	6.32e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GSK3B—Alzheimer's disease	3.57e-06	6.29e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—LPL—Alzheimer's disease	3.56e-06	6.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CREB1—Alzheimer's disease	3.54e-06	6.24e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCL2—Alzheimer's disease	3.53e-06	6.24e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOTCH1—Alzheimer's disease	3.53e-06	6.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—INS—Alzheimer's disease	3.52e-06	6.21e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO1—Alzheimer's disease	3.49e-06	6.15e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS1—Alzheimer's disease	3.49e-06	6.15e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1—Alzheimer's disease	3.48e-06	6.13e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—NOS3—Alzheimer's disease	3.47e-06	6.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCL2—Alzheimer's disease	3.46e-06	6.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NOS3—Alzheimer's disease	3.43e-06	6.05e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2D6—Alzheimer's disease	3.42e-06	6.03e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1—Alzheimer's disease	3.4e-06	6.01e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—MTHFR—Alzheimer's disease	3.4e-06	6e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GSK3B—Alzheimer's disease	3.31e-06	5.85e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREB1—Alzheimer's disease	3.29e-06	5.8e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—INS—Alzheimer's disease	3.27e-06	5.77e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—BCHE—Alzheimer's disease	3.24e-06	5.72e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCL2—Alzheimer's disease	3.22e-06	5.68e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	3.2e-06	5.65e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CALM1—Alzheimer's disease	3.18e-06	5.6e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—APOE—Alzheimer's disease	3.16e-06	5.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—Alzheimer's disease	3.16e-06	5.58e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—Alzheimer's disease	3.15e-06	5.56e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—Alzheimer's disease	3.14e-06	5.54e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—Alzheimer's disease	3.14e-06	5.53e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—Alzheimer's disease	3.13e-06	5.53e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—Alzheimer's disease	3.13e-06	5.52e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—Alzheimer's disease	3.11e-06	5.49e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—Alzheimer's disease	3.1e-06	5.46e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—Alzheimer's disease	3.08e-06	5.44e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—Alzheimer's disease	3.08e-06	5.44e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—Alzheimer's disease	3.08e-06	5.43e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—Alzheimer's disease	3.06e-06	5.4e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLCB1—Alzheimer's disease	3.06e-06	5.4e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.99e-06	5.28e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.98e-06	5.26e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—Alzheimer's disease	2.98e-06	5.25e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCA1—Alzheimer's disease	2.96e-06	5.23e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.95e-06	5.21e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—Alzheimer's disease	2.95e-06	5.2e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—Alzheimer's disease	2.93e-06	5.17e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—Alzheimer's disease	2.87e-06	5.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—Alzheimer's disease	2.87e-06	5.06e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK8—Alzheimer's disease	2.85e-06	5.02e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—Alzheimer's disease	2.84e-06	5.01e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK8—Alzheimer's disease	2.83e-06	5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—Alzheimer's disease	2.82e-06	4.98e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PPARG—Alzheimer's disease	2.76e-06	4.86e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK8—Alzheimer's disease	2.71e-06	4.78e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—INS—Alzheimer's disease	2.7e-06	4.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—Alzheimer's disease	2.7e-06	4.77e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.7e-06	4.76e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—Alzheimer's disease	2.67e-06	4.72e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—Alzheimer's disease	2.66e-06	4.69e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.64e-06	4.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—Alzheimer's disease	2.63e-06	4.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—Alzheimer's disease	2.62e-06	4.62e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—Alzheimer's disease	2.61e-06	4.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—Alzheimer's disease	2.6e-06	4.59e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.6e-06	4.58e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARGC1A—Alzheimer's disease	2.55e-06	4.51e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—INS—Alzheimer's disease	2.55e-06	4.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—Alzheimer's disease	2.54e-06	4.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—Alzheimer's disease	2.5e-06	4.42e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.46e-06	4.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—Alzheimer's disease	2.46e-06	4.33e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.45e-06	4.33e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—Alzheimer's disease	2.43e-06	4.29e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—Alzheimer's disease	2.42e-06	4.27e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—Alzheimer's disease	2.41e-06	4.26e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK8—Alzheimer's disease	2.41e-06	4.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—Alzheimer's disease	2.4e-06	4.24e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—Alzheimer's disease	2.4e-06	4.23e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—Alzheimer's disease	2.37e-06	4.18e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LPL—Alzheimer's disease	2.33e-06	4.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—Alzheimer's disease	2.3e-06	4.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—Alzheimer's disease	2.27e-06	4.01e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK8—Alzheimer's disease	2.24e-06	3.95e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—Alzheimer's disease	2.23e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—Alzheimer's disease	2.23e-06	3.94e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—Alzheimer's disease	2.22e-06	3.92e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—Alzheimer's disease	2.17e-06	3.83e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—Alzheimer's disease	2.09e-06	3.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—Alzheimer's disease	2.08e-06	3.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—Alzheimer's disease	2.07e-06	3.64e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	2.04e-06	3.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—Alzheimer's disease	2.04e-06	3.6e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—Alzheimer's disease	2e-06	3.53e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—Alzheimer's disease	1.99e-06	3.5e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—Alzheimer's disease	1.98e-06	3.49e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CALM1—Alzheimer's disease	1.96e-06	3.45e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—APOE—Alzheimer's disease	1.95e-06	3.44e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—Alzheimer's disease	1.93e-06	3.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—Alzheimer's disease	1.9e-06	3.34e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—Alzheimer's disease	1.89e-06	3.34e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—Alzheimer's disease	1.82e-06	3.21e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—Alzheimer's disease	1.81e-06	3.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—Alzheimer's disease	1.73e-06	3.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—Alzheimer's disease	1.72e-06	3.03e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARG—Alzheimer's disease	1.7e-06	3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—Alzheimer's disease	1.68e-06	2.96e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—Alzheimer's disease	1.68e-06	2.96e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—Alzheimer's disease	1.67e-06	2.94e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INS—Alzheimer's disease	1.67e-06	2.94e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—Alzheimer's disease	1.6e-06	2.82e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—Alzheimer's disease	1.58e-06	2.78e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—Alzheimer's disease	1.57e-06	2.77e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—Alzheimer's disease	1.56e-06	2.75e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—Alzheimer's disease	1.54e-06	2.71e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—Alzheimer's disease	1.46e-06	2.58e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—Alzheimer's disease	1.45e-06	2.56e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—Alzheimer's disease	1.44e-06	2.55e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—Alzheimer's disease	1.43e-06	2.52e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—Alzheimer's disease	1.42e-06	2.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—Alzheimer's disease	1.34e-06	2.36e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—Alzheimer's disease	1.32e-06	2.33e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—Alzheimer's disease	1.09e-06	1.92e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.03e-06	1.81e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—Alzheimer's disease	6.71e-07	1.18e-05	CbGpPWpGaD
